Suppr超能文献

新型冠状病毒肺炎急性期相关指标对肺纤维化的影响及随访评估

Effects of acute-phase COVID-19-related indicators on pulmonary fibrosis and follow-up evaluation.

作者信息

Wang Qiong, Zhou Ying, Jing Fangxue, Feng Yingying, Ma JiangPo, Xue Peng, Dong Zhaoxing

机构信息

Health Science Center, Ningbo University, Ningbo, 315211, China.

Department of Respiratory Infection, ZhenHai Hospital of Traditional Chinese Medicine, Ningbo, 315200, China.

出版信息

Eur J Med Res. 2024 Dec 18;29(1):585. doi: 10.1186/s40001-024-02197-5.

Abstract

BACKGROUND

Post-COVID-19 pulmonary fibrosis is a significant long-term respiratory morbidity affecting patients' respiratory health. This exploratory study aims to investigate the incidence, clinical characteristics, and acute-phase risk factors for pulmonary fibrosis in COVID-19 patients. Additionally, it evaluates pulmonary function and chest CT outcomes to provide clinical evidence for the early identification of high-risk patients and the prevention of post-COVID-19 pulmonary fibrosis.

METHODS

We retrospectively analyzed 595 patients hospitalized for COVID-19 from January 2022 to July 2023. Patients were divided into fibrosis and nonfibrosis groups on the basis of imaging changes. Baseline data, including demographics, disease severity, laboratory indicators, and chest imaging characteristics, were collected. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors for pulmonary fibrosis. Pulmonary function and chest CT follow-ups were conducted for the fibrosis group. The data were processed via SPSS 26.0, with P < 0.05 considered statistically significant.

RESULTS

The incidence of pulmonary fibrosis was 4.37%, with 2.08% in moderate cases and 8.22% in severe cases. Significant differences were found between the fibrosis and nonfibrosis groups in sex; disease severity; NLR; ALB and LDH levels; and percentages of lung reticular lesions, consolidations, and GGOs (P < 0.05). Multivariate analysis revealed LDH (OR = 1.004, 95% CI 1.000-1.007, P = 0.035), ALB (OR = 0.871, 95% CI 0.778-0.974, P = 0.015), lung reticular lesion volume (OR = 1.116, 95% CI 1.040-1.199, P = 0.002), and lung consolidation volume (OR = 1.131, 95% CI 1.012-1.264, P = 0.030) as independent risk factors. The follow-up results revealed significant improvements in pulmonary function, specifically in the FVC%, FEV1%, and DLCO%, but not in the FEV1/FVC. Quantitative chest CT analysis revealed significant differences in lung reticular lesions, consolidation, and GGO volumes but no significant difference in honeycomb volume.

CONCLUSIONS

The incidence of pulmonary fibrosis post-COVID-19 increases with disease severity. LDH, ALB, lung reticular lesions, and consolidation volume are independent risk factors for patients with fibrosis.

摘要

背景

新型冠状病毒肺炎(COVID-19)后肺纤维化是一种严重的长期呼吸系统疾病,影响患者的呼吸健康。本探索性研究旨在调查COVID-19患者肺纤维化的发病率、临床特征和急性期危险因素。此外,评估肺功能和胸部CT结果,为早期识别高危患者和预防COVID-19后肺纤维化提供临床依据。

方法

我们回顾性分析了2022年1月至2023年7月因COVID-19住院的595例患者。根据影像学变化将患者分为纤维化组和非纤维化组。收集基线数据,包括人口统计学、疾病严重程度、实验室指标和胸部影像学特征。进行单因素和多因素逻辑回归分析,以确定肺纤维化的独立危险因素。对纤维化组进行肺功能和胸部CT随访。数据通过SPSS 26.0进行处理,P<0.05被认为具有统计学意义。

结果

肺纤维化的发病率为4.37%,中度病例为2.08%,重度病例为8.22%。纤维化组和非纤维化组在性别、疾病严重程度、中性粒细胞与淋巴细胞比值(NLR)、白蛋白(ALB)和乳酸脱氢酶(LDH)水平以及肺网状病变、实变和磨玻璃影(GGO)的百分比方面存在显著差异(P<0.05)。多因素分析显示,LDH(比值比[OR]=1.004,95%可信区间[CI] 1.000-1.007,P=0.035)、ALB(OR=0.871,95%CI 0.778-0.974,P=0.015)、肺网状病变体积(OR=1.116,95%CI 1.040-1.199,P=0.002)和肺实变体积(OR=1.131,95%CI 1.012-1.264,P=0.030)是独立危险因素。随访结果显示肺功能有显著改善,特别是在用力肺活量百分比(FVC%)、第一秒用力呼气容积百分比(FEV1%)和一氧化碳弥散量百分比(DLCO%)方面,但在FEV1/FVC方面无显著改善。定量胸部CT分析显示肺网状病变、实变和GGO体积有显著差异,但蜂窝状体积无显著差异。

结论

COVID-19后肺纤维化的发病率随疾病严重程度增加。LDH、ALB、肺网状病变和实变体积是纤维化患者的独立危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a8/11657883/8e5ede9ca29f/40001_2024_2197_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验